An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

The aim of the study is to assess the efficacy and safety of BCD-248 as a therapy for relapsing and/or refractory multiple myeloma.

Trial Details

NCT ID
NCT06668792
Phase
PHASE2
Sponsor
Biocad
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • BCD-248
Locations (sample)
  • Kaliningrad, Russia|54.70639,20.51102
  • Kazan', Russia|55.78874,49.12214
  • Kirov, Russia|58.59809,49.65783
  • Krasnoyarsk, Russia|56.03742,92.93136
  • Moscow, Russia|55.75204,37.61781

Key Eligibility Criteria

  • Signed informed consent form.
  • Age ≥18 years.
  • Documented diagnosis of multiple myeloma according to the IMWG criteria.
  • Measurable disease at screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →